Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

NCT03658031 is registered in ClinicalTrials.gov with Hamad Medical Corporation as lead sponsor.

NCT NCT03658031
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03658031 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction
Lead sponsor
Hamad Medical Corporation
Phase
Phase 3
Overall status
Unknown status
Start date
March 1, 2019
Completion date
January 31, 2021
Enrollment
576 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cvd, myocardial infarction, prediabetes, t2dm (type 2 diabetes mellitus)